Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression

Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression

To date, there is no cure for Parkinson’s disease (PD). There is a pressing need for anti-neurodegenerative therapeutics that can slow or halt PD progression by targeting underlying disease mechanisms. Specifically, preventing the build-up of alpha-synuclein (αSyn) and its aggregated and mutated for...

Full description

Bibliographic Details
Main Authors: Benjamin W. Schlichtmann, Bharathi N. Palanisamy, Emir Malovic, Susheel K. Nethi, Piyush Padhi, Monica Hepker, Joseph Wurtz, Manohar John, Bhupal Ban, Vellareddy Anantharam, Anumantha G. Kanthasamy, Balaji Narasimhan, Surya K. Mallapragada
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Biomolecules
Subjects:
scFv
polyanhydride nanoparticles
AAV
Parkinson’s disease
alpha synuclein
Online Access:https://www.mdpi.com/2218-273X/13/8/1203

Internet

https://www.mdpi.com/2218-273X/13/8/1203

Similar Items